Liver transplant bleeding study pulled before starting
NCT ID NCT06764927
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to see if a new concentrated fibrinogen product works better than the standard one for controlling bleeding in liver transplant patients. It planned to enroll adults having a cadaveric liver transplant who were at risk for low fibrinogen levels. However, the study was withdrawn before any participants were enrolled, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER DISEASE REQUIRING TRANSPLANT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UPMC Montefiore Hospital
Pittsburgh, Pennsylvania, 15213, United States
-
UPMC Presbyterian Hospital
Pittsburgh, Pennsylvania, 15213, United States
-
University of Cincinnati
Cincinnati, Ohio, 45221, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a wearable glucose sensor be trusted in the ICU? new study aims to find out
- New device could keep donor livers healthier before transplant
- Online prehab program aims to boost strength in liver transplant patients
- Pre-Surgery carb drink may speed liver transplant recovery
- Liver transplant showdown: which method works best for colon cancer patients?
- New blood product tested for safer liver transplants